<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51903">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01843530</url>
  </required_header>
  <id_info>
    <org_study_id>BER-1272-0058-I</org_study_id>
    <nct_id>NCT01843530</nct_id>
  </id_info>
  <brief_title>Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema</brief_title>
  <official_title>Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a randomized, double-blind, two arms, multicenter, Phase III study of Berinert
      for treatment of ACE induced Angioedema.

      This study should show that Berinert shortens the time to complete resolution of signs and
      symptoms of acute ACE-induced angioedema of the upper airway tract compared to placebo when
      given on top of standard treatment. This study should also compare the time to onset of
      relief as defined by an at least one point reduction on the severity scale of ACE-induced
      angioedema with Berinert versus placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>time of resolution</measure>
    <time_frame>07/2013 until 12/2014</time_frame>
    <safety_issue>No</safety_issue>
    <description>Berinert shortens the time to complete resolution of signs and symptoms of acute ACE-induced angioedema of the upper airway tract compared to placebo when given on top of standard treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Acute ACE-induced Angioedema</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cortisone, Clemastin + BERINERT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cortinsone, Clemastin + NaCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berinert</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clemastin</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cortisone acetate</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl</intervention_name>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent to participate in the study and ability to fulfil all study
             requirements

          -  Male or female patients aged &gt;=18 years

          -  Patients with ACE induced angioedema (grade II-III) with imminent airway obstruction
             admitted to an Emergency department

          -  Patient is being treated with ACEi

          -  Patient must have acute angioedema attack caused by ACEi

          -  Treatment should be administered within 10 hours after onset of the angioedema

          -  Patients with angioedema of the head and/or neck (face, lips, cheeks, tongue, soft
             palate/uvula, pharynx and larynx)

          -  Male participants and female participants who are not capable of bearing children or
             who use a method of contraception that is medically approved by the health authority
             of the respective country

          -  Signed patient information consent form

        Exclusion Criteria:

          -  Diagnosis of angioedema of other genesis: e.g. hereditary angioedema, C1-inhibitor
             deficiency, allergic edema, anaphylaxis, insect bite, trauma, abscess, local
             inflammation, local tumour, post-operative or post-radiogenic edema, salivary gland
             disorders

          -  Participation in a clinical study in the past 30 days

          -  Patients with simultaneous itchiness of skin (acute urticaria)

          -  Patients with a history of angioedema before taking ACEi

          -  History of hypersensitivity to any of the study drugs or medicine with a similar
             chemical structure.

          -  Pregnancy and/or breastfeeding

          -  Mental retardation of the patient with restriction of general judgment and awareness

          -  History of drug abuse (including alcohol and alcoholic liver disorders)

          -  Potentially unreliable patients

          -  Patients who are not suitable for the study in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murat Bas, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum rechts der Isar</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beate Schossow</last_name>
    <phone>+49(0)89 4140-5840</phone>
    <email>beate.schossow@mri.tum.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charite, Universitätsmedizin Berlin, Campus Virchow Kliniken</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Förster, Dr.</last_name>
      <phone>+49 30450 655</phone>
      <phone_ext>227</phone_ext>
      <email>ulrike.foerster@charite.de</email>
    </contact>
    <investigator>
      <last_name>Ulrike Förster, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Hals-Nasen-Ohren Klinik</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murat Bas, Dr.</last_name>
      <email>m.bas.hno@googlemail.com</email>
    </contact>
    <investigator>
      <last_name>Murat Bas, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilian-Universität</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Stelter, Dr.</last_name>
      <phone>+49 89 7095</phone>
      <phone_ext>3888</phone_ext>
      <email>klaus.stelter@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Klaus Stelter, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, HNO</name>
      <address>
        <city>Ulm</city>
        <zip>89070</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Greve, Dr.</last_name>
      <phone>+49 731 500</phone>
      <phone_ext>59501</phone_ext>
      <email>jens.greve@uniklinik-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>, .</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jens Greve, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>April 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angioedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cortisone acetate</mesh_term>
    <mesh_term>Cortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
